Why does cancer therapy lack effective anti-metastasis drugs?

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 207-211

  Weber, Georg F ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Cancer; Clinical trials; Drug development; Metastasis

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; 4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; AE 941; ANTIMETASTATIC AGENT; BATIMASTAT; CILENGITIDE; CLODRONIC ACID; ETARACIZUMAB; FRESOLIMUMAB; GEFITINIB; IBANDRONIC ACID; INCYCLINIDE; INTETUMUMAB; LERDELIMUMAB; MARIMASTAT; METELIMUMAB; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NERATINIB; PLERIXAFOR; PRINOMASTAT; REBIMASTAT; REPARIXIN; SOLIMASTAT; TANOMASTAT; TETRACYCLINE; TRABEDERSEN; UNINDEXED DRUG; VOLOCIXIMAB;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL PROLIFERATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG USE; FATALITY; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TREATMENT FAILURE;

EID: 84870365240     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.025     Document Type: Review

References (11)

1. Weber G.F. Molecular Mechanisms of Cancer 2007, Springer, Dordrecht.
2. Ewing J. Neoplastic Diseases. A Treatise on Tumors 1928, W.B. Saunders Co., Philadelphia/London.
3. Poste G., Doll J., Hart I.R., Fidler I.J. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res. 1980, 40:1636-1644.
4. Weber G.F. Molecular mechanisms of metastasis. Cancer Lett. 2008, 270:181-190.
5. Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat. Rev. Drug Disc. 2012, 11:479-497.
6. Iiizumi M., Liu W., Pai S.K., Furuta E., Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim. Biophys. Acta 2008, 1786:87-104.
7. Weber G.F., Lett S., Haubein N. Osteopontin is a marker for cancer aggressiveness and patient survival. Brit. J. Cancer 2010, 103:861-869.
8. Steeg P.S., Camphausen K.A., Smith Q.R. Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 2011, 11:352-363.
9. Steeg P.S. Perspective: the right trials. Nature 2012, 485:S58-S59.
10. Grove A. Rethinking clinical trials. Science 2011, 333:1679.
11. Esserman L.J., Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011, 306:2608-2609.